Halozyme Therapeutics, Inc. (HALO) Stock Overview
Explore Halozyme Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Halozyme Therapeutics, Inc. (HALO)
Key Financials
Key Financials
Market Cap
9B
P/E Ratio
25.70
EPS (TTM)
$4.62
ROE
1.26%
HALO Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Halozyme Therapeutics, Inc. (HALO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 54.05, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $80.93.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 25.70 and a market capitalization of 9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.